ArticleFolia microbiologica2026
Linsitinib: a tyrosine kinase inhibitor with dual host-parasite targeting potential against leishmaniasis.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Leishmaniasis is a vector-borne parasitic disease caused by Leishmania spp., that contributes substantially to global morbidity. Considering the toxicity, drug resistance and limited efficacy of current therapies, drug repositioning represents an efficient approach for identifying novel antileishmanial agents from existing pool of drugs. In this context, we evaluated antileishmanial potential of Linsitinib, a known tyrosine kinase inhibitor and an anticancer molecule in advance stages of development. Linsitinib demonstrated potent anti-proliferative activity with IC
Identifiers
42825988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.